We herein present the bioguided fractionation of S. cumini bark decoction for antiplasmodial activity, and the isolation of active and non-active ellagitannins, one of them elucidated as a new natural product. Activity investigation was based on the reduction of P. falciparum (PfK1) parasitaemia in vitro and the inhibition of β-hematin formation, a known mechanism of action of some antimalarial drugs [5] .
High performance liquid chromatography coupled with UV detection and electrospray mass spectrometry (HPLC/UV/ESI-MS), in the negative mode, was conducted for the crude extract, showing the presence of ellagic acid, with a pseudomolecular ion at m/z 301 [M-H] -. Other compounds presented molecular pseudomolecular ions corresponding to known ellagitannins. However, the exact structure of these compounds could not be determined on the basis of on-line data. Thus, a fractionation procedure was established in order to isolate compounds for complete structure elucidation and activity determination. As a preliminary activity investigation, an HPLC microfractionation was conducted and 40 fractions of 1 mL were collected in a 96-well plate. Fractions were tested for the inhibition of β-hematin formation in an in-house assay, particularly developed for the screening of plant extracts and fractions. By this means, two peaks could be linked to significant activity, one at 6.8 min, and the other at 23.2 min, corresponding to gallic and ellagic acids, respectively.
Four major fractions (A-D) were obtained by centrifugal partition chromatography (CPC). All fractions were tested against P. falciparum in vitro. Fraction C was considered highly active, with an IC 50 value lower than 0.25 µg/mL, while fractions B and D were considered moderately active with IC 50 values of 27.1 and 19.8 µg/mL, respectively.
Gallic acid (1, 22 mg) was obtained as yellow crystals by filtration of fraction B. Fraction C was further fractionated by medium pressure liquid chromatography (MPLC) followed by semipreparative HPLC isolation to give ellagic acid (2, 16 mg) Known compounds (1, 2, 4 and 5) had their structures confirmed by the analysis of their spectral data, which were compared with those in the literature. Compound 3 was elucidated by the careful analysis of spectral data, including high resolution mass spectrometry, 1 H, 13 13 , the same as that of several methylellagic acid glucosides previously published [8] [9] [10] . The 1 H NMR spectrum of 3 showed a singlet at δ H 4.05 indicating the presence of one O-methyl substituent. Enzymatic hydrolysis with β-D-glucosidase was successfully achieved, confirming a β-D-glucopyranoside moiety, and the connectivity between protons of the sugar moiety was established by analysis of the COSY correlations. The attachment of the sugar at C-3' could be determined by the HMBC correlation between the anomeric proton (δ H 5.06) and C-3' (δ C 141.6), together with the upfield shift of H-5' (δ H 7.71 instead of 7.80) compared with a glucoside substitution at position 4' [11] . The methoxyl substitution at C-3 was determined by the 13 C shift of ca. 64 ppm instead of the typical value of 57 ppm of an O-methyl substitution at C-4 [8] . According to previous work [12] , 4-O-methylellagic acid derivatives present a NOESY correlation between the methoxyl signal and that of H-5. This correlation was not observed in the NOESY spectrum of 3. It is also important to notice that both compounds 3 and 5, having a sugar substitution at C-3', presented 13 C NMR shifts of C-1' at δ C 115.6 and 114.4, respectively, rather than 112.2, as in ellagic acid (2), and 112.6 in its derivative with the sugar moiety at C-4'(4). Therefore, this shift difference is suggested as a useful tool in the differentiation of sugar substitution patterns at C-3'and C-4'.
Isolated compounds were tested against P. falciparum (PfK1) and for their cytotoxicity on human fibroblasts. IC 50 values are presented in Table  1 . According to these results, none of the compounds were considered cytotoxic and only ellagic acid was able to reduce in vitro parasitaemia. Interestingly, ellagic acid derivatives were not active.
The inhibition of β-hematin formation has previously been raised as one of the mechanisms of action for the in vitro antiplasmodial activity of ellagic acid [13] . When the activity on the inhibition of β-hematin formation was assessed for isolated compounds, only 1 and 2 presented a significant inhibition (Figure 1 ).
Throughout the validation process of our in-house βhematin assay, gallic acid (1) was actually considered as an interfering compound, with no reduction of in vitro parasitaemia. On the other hand, the inhibition of β-hematin formation by ellagic acid (5) has previously been investigated and two possible explanations have been raised: 1) its flat molecular structure with a high electronic density would be able to form π-π interaction complexes with hematin monomers, and 2) the aryl hydroxyl groups of ellagic acid would be able to form coordination bonds with the Fe(III) of hematin [14] . In the case of compounds 3-5, the obtained results are in accordance with the second explanation, since they are OH-substituted derivatives presenting no significant inhibition on β-hematin formation.
Experimental
Plant material and extraction: Syzygium cumini (L.) Skeels (Myrtaceae) stem bark was collected in the city of João Pessoa, state of Paraíba, Brazil, in July 2004. The bark was dried at 60°C, ground, and 400 g was extracted by decoction in 2 L distilled water for 15 min. The resulting extract was filtered and freezedried to give 80 g of powdered extract. 
HPLC/UV/ESI-MS:

Centrifugal partition chromatography (CPC):
Fractionations were conducted on a counter-current chromatograph CCC-1000 (Pharma-Tech Research Corp.) equipped with dynamic coils of 650 mL total volume. The rotation speed was set at 1000 rpm. Two LC-300 pumps (Scientific Systems Inc.) were used to pump either upper or lower phase into the coils at a flow rate of 3.0 mL/min for each phase. Samples were diluted in 30 mL of a mixture of upper and lower phases (1:1) and introduced through the injection loop. Crude extract (20 g) was chromatographed using the solvent system tert-butylmethyl-ether -n-butanol -acetonitrile (2:2:1:5) + 0.05% TFA. The lower phase was used as mobile phase, followed by phase inversion after 13 h.
Medium pressure liquid chromatography (MPLC):
The equipment used consisted of a Büchi B-681 pump, a Knauer K 2001 UV detector, a Pharmacia LKB Rec 1 recorder, and an automatic Büchi B-684 fraction collector. Lichroprep ® C 18 stationary phase (15-25 µm, Merck) was packed in a pressure-resistant column. A stepwise gradient of MeOH-water was employed as mobile phase, starting at 5:95 and gradually increasing to 100:0, according to the online UV chromatographic profile. Fraction C (500 mg) was placed in an introduction cartridge after having been mixed with 3 times its weight of stationary phase. The fractionation provided 4 major fractions (C1-C4). Simões-Pires et al.
Semi-preparative high performance liquid chromatography:
A Shimadzu LC-8A binary pump equipped with a SPD-10A VP Shimadzu UV-Vis detector (Kyoto, Japan) was employed at a flow rate of 10 mL/min. A Symmetry Prep TM C 18 column (150 x 19 mm i.d., 7 µm) was used. The solvent system was A) water + 0.05% TFA, and B) MeOH + 0.05% TFA in isocratic mode. Fraction C3 (32 mg) and D (28 mg) were chromatographed using 30% and 35% B as mobile phase, respectively.
Antiplasmodial activity assay:
A chloroquineresistant strain of P. falciparum (PfK1) was used. The strain was maintained in RPMI-1640 medium supplemented with 0.37 mM hypoxanthine, 25 mM Hepes, 25 mM NaHCO 3 , and 0.5% Albumax ® with 2-4% washed human erythrocytes. All cultures and assays were conducted at 37°C. Extract/compound stock solutions were prepared in 100% DMSO at 20 mg/mL or mM. Samples were serially pre-diluted (2fold or 4-fold) in DMSO followed by a further dilution in demineralized water to assure a final intest DMSO concentration of <1%. Assays were performed in 96-well microtiter plates, each well containing 10 µL of the watery compound dilutions together with 190 µL of the malaria parasite inoculum (1% parasitaemia, 2% HCT). Parasite growth was compared with untreated-infected (100% growth) and uninfected-controls (0% growth). After 72 h incubation at 37°C, plates were frozen at -20°C. After thawing, 20 µL of each well was transferred onto another plate together with 100 µL Malstat TM reagent and 20 μL of a 1:1 mixture of PES (phenazine ethosulfate, 0.1 mg/mL) and NBT (Nitro Blue Tetrazolium Grade III, 2 mg/mL). The plates were kept out of light for 2 h and change in color was measured spectrophotometrically at 655 nm. The results were expressed as % reduction in parasitaemia compared with control wells and IC 50 values were calculated. Compounds/extracts were tested at 5 concentrations (64, 16, 4, 1 and 0.25 μM or μg/mL). Chloroquine was used as reference compound (IC 50 =0.35 µM).
Cytotoxicity assay:
Human fibroblast MRC-5 SV2 cells were cultured in MEM + Earl's salts-medium, supplemented with L-glutamine, NaHCO 3 and 5% inactivated fetal calf serum. All cultures and assays were conducted at 37°C under an atmosphere of 5% CO 2 . Compound/extract stock solutions were prepared in 96-well microtiter plates, as described for antiplasmodial activity. Each well contained 10 µL of the watery compound dilutions together with 190 µL of MRC-5 SV2 inoculum (3x10 4 cells/mL). Cell growth was compared with untreated-control wells (100% cell growth) and medium-control wells (0% cell growth). After 3 days incubation, cell viability was assessed fluorimetrically after addition of 50 µL resazurin per well. After 4 h at 37°C, fluorescence was measured (λ ex 550 nm, λ em 590 nm). Results were expressed as % reduction in cell growth/viability compared with control wells and IC 50 values were determined. Compounds/extracts were tested at 5 concentrations (64, 16, 4, 1 and 0.25 μM or µg/mL), using tamoxifen as cytotoxic reference compound (IC 50 = 10.6 µM).
β-Hematin formation inhibition assay: Solutions
(50 mM) of pure compounds were prepared in 1.0 M HCl-MeOH-DMSO (5:3:2). Compounds/fractions were distributed in a 96-well plate. A previously established Phiβ-assay [15] was used to develop the in-house inhibition assay, based on β-hematin photocolorimetric determination. Colorimetric measurements were performed at 405 nm in an EL-808 apparatus (Bio-Tek Instruments, Inc.) and qualitative results were statistically obtained by I Analysis . 
